Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

950
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
950
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

563
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
563
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

994
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
994

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pharmaceutical interviews in onco-haematology and so-called 'natural' products: An example illustrated by cannabidiol (CBD)].

Bulletin du cancer·2025
Same author

Baclofen in the treatment of alcohol use disorder: tailored doses matter.

Alcohol and alcoholism (Oxford, Oxfordshire)·2024
Same author

Baclofen in alcohol use disorder: An analysis of the data provided by the French "Temporary Recommendation for Use" 2014-2017 cohort.

Frontiers in psychiatry·2022
Same author

Binge Eating Disorders in Antipsychotic-Treated Patients With Schizophrenia: Prevalence, Antipsychotic Specificities, and Changes Over Time.

Journal of clinical psychopharmacology·2021
Same author

SIRT1 activation rescues the mislocalization of RNA-binding proteins and cognitive defects induced by inherited cobalamin disorders.

Metabolism: clinical and experimental·2019
Same author

Editorial: Baclofen in the Treatment of Alcohol Use Disorder.

Frontiers in psychiatry·2019

Related Experiment Video

Updated: Apr 16, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.9K

Colitis possibly induced by quetiapine.

Renaud de Beaurepaire1, Isabelle Trinh1, Sophie Guirao1

  • 1GHPG, Villejuif, France.

BMJ Case Reports
|February 28, 2015
PubMed
Summary

Quetiapine, an antipsychotic, may cause necrotising ischaemic colitis, especially when combined with anticholinergics like tropatepine. This rare adverse event required surgical intervention in a bipolar disorder patient.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Clinical Case Reports

Background:

  • Bipolar disorder management often involves multiple medications.
  • Antipsychotics like quetiapine are commonly prescribed.
  • Anticholinergic drugs can have various side effects.

Observation:

  • A patient with bipolar disorder developed severe abdominal pain and constipation after initiating quetiapine.
  • Imaging revealed significant colon distention and signs of pre-perforation.
  • Histology confirmed necrotising ischaemic colitis post-surgery.

Findings:

  • This is the first reported case of ischaemic colitis linked to quetiapine monotherapy.
  • The co-prescription of tropatepine, an anticholinergic, was identified as a likely cofactor.

More Related Videos

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

1.0K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.3K

Related Experiment Videos

Last Updated: Apr 16, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.9K
Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

1.0K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.3K
  • Necrotising ischaemic colitis is a rare but serious adverse drug reaction.

    • Implications:

    • Clinicians should exercise caution when co-prescribing quetiapine with anticholinergic agents.
    • Awareness of this potential drug interaction is crucial for patient safety.
    • Further research may be needed to elucidate the mechanisms of this adverse event.